By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference 2/2/2016 9:41:23 AM
Soligenix (SNGX) Provides 2016 Business Outlook 1/26/2016 7:42:04 AM
Vista Partners Updates Coverage On Soligenix (SNGX) (Ticker: SNGX); Price Target $7.00 12/22/2015 3:45:50 PM
SciClone Pharmaceuticals, Inc. (SCLN) To Pursue Development Of SGX942 In China Following Soligenix (SNGX)' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis 12/21/2015 7:31:40 AM
Soligenix (SNGX) Will Host A Conference Call To Update Shareholders On Recent Positive Clinical Results And Company Development Milestones 12/16/2015 9:25:20 AM
Soligenix (SNGX) Announces Positive Preliminary Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 12/16/2015 6:48:33 AM
Soligenix (SNGX) Announces Initiation Of Its Pivotal Phase 3 Clinical Trial Of SGX301 (Synthetic Hypericin) For The Treatment Of Cutaneous T-Cell Lymphoma 12/14/2015 6:20:41 AM
Soligenix (SNGX) Receives $490,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program 12/9/2015 6:24:03 AM
Soligenix (SNGX) Provides Clinical Program Updates For December 2015 12/4/2015 7:26:05 AM
Soligenix (SNGX) Announces Recent Highlights and Third Quarter 2015 Financial Results 11/12/2015 10:11:04 AM